Entrada Therapeutics Azioni (NASDAQ: TRDA)

Ultime notizie per Entrada Therapeutics (NASDAQ:TRDA) Azioni

Entrada Therapeutics

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics Inc

Lotus continues to achieve top-rate growth among traditional luxury car brands, delivering 7,543 vehicles1&nbsp;in the first nine months of 2024, representing a year-on-year increase of&nbsp;134%. Global allocation in terms of deliveries remained well-distributed, with Europe, China, North America and the Rest of the World regions each contributing about&nbsp;20-35%&nbsp;of the total deliveries. In the&nbsp;third quarter&nbsp;of 2024, Emeya (GT, Sedan) was delivered to Europe, whilst Eletre (SUV) reached markets including the GCC, Japan and Korea.

News

Reported Earlier, Lotus Technology Reports 134% YoY Vehicle Delivery Surge In First Nine Months Of 2024

Macro Economic Events

Econ #s

Economics

U.K. Retail Sales (YoY) For September 3.9% Vs. 3.2% Est.; 2.3% (Revised) Prior

U.K. Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.0% Prior

U.K. Core Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.1% Prior

U.K. Core Retail Sales (YoY) For September 4.0% Vs. 3.2% Est.; 2.2% (Revised) Prior

Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Co-CEO&nbsp;Ted Sarandos on Thursday outlined why the streaming giant continues to hold an edge over YouTube, a subsidiary of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: During Netflix&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter earnings</a> call, a question about&nbsp;YouTube&#8217;s growing share of TV&nbsp;consumption was raised.
In response, Sarandos highlighted Netflix&#8217;s commitment to investing in premium content to increase viewer engagement, stating, &#8220;Netflix is the best place&nbsp;for premium stories because we&#8217;re&nbsp;the home to the best&nbsp;storytellers.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
Regarding YouTube, he said, &#8220;When I look at YouTube specifically, I&#8217;d say look, we compete directly with YouTube for people&#8217;s time, for the time they spend on that TV screen. But we have very different strengths.&#8221;
Another, Netflix Co-CEO Greg Peters added that Netflix plays a crucial role for consumers seeking high-quality movies and TV shows, and for creators looking for partners willing to share the inherent risks of bringing stories to life.
&#8220;A Hundred Years of Solitude, Senna, both coming from Latin America, which are huge, ambitious projects. It&#8217;s hard to imagine how those kind of big creative bets would be possible with YouTube&#8217;s model,&#8221; Peters stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Netflix&#8217;s third-quarter financial results showed a 15% year-over-year increase in revenue, beating Street consensus estimates.
Moreover, Netflix&#8217;s recent foray into live sports programming indicates a strategic shift from its traditional on-demand model. This move aims to capture high-impact moments and the <a href="https://www.benzinga.com/general/entertainment/24/10/41395213/netflixs-200b-hour-problem-why-live-sports-are-just-a-drop-in-the-streaming-ocean">excitement of global live events</a>, further enhancing viewer engagement.
During the <a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game" target="_blank" rel="noreferrer noopener">second-quarter earnings</a> call, Netflix executives were asked questions about YouTube.
At the time, Sarandos&nbsp;said, &#8220;So our two services — us and YouTube represent about 50% of all streaming to the TV in the U.S. and we use the U.S. only because that's where we have the data.&#8221;
&#8220;So really what we're focused on here is focusing ourselves on that other 80% of total TV time that isn't going to either us or YouTube,&#8221; he said in July.
Sarandos <a href="https://www.benzinga.com/general/entertainment/24/07/39853498/netflix-aims-to-capture-broader-tv-market-sees-youtube-as-both-competitor-and-partner-we-ki">reiterated Netflix&#8217;s commitment to focus</a> on the remaining 80% of the market during the third-quarter call too.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chips In US For iPhone Maker</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Entertainment

Equities

Markets

Tech

General

GOOG

GOOGL

NFLX

Netflix's Ted Sarandos Downplays Concerns Of YouTube's Growing Share Of TV Consumption: 'We're The Home To The Best Storytellers'

Orders and deliveries
In Q3, net order intake decreased by 8% to 43,234 trucks and deliveries decreased by 16% to 46,266 units. Deliveries of heavyduty trucks decreased by 9%, of medium-duty trucks by 21% and of light-duty trucks by 61%.

Earnings

VLVLY

Volvo's Q3 Saw 8% Drop In Net Order Intake To 43,234 Trucks, With Deliveries Down 16% To 46,266 Units

Volvo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLVLY#OTC">VLVLY</a>) reported quarterly earnings of $0.47 per share. This is a 26.18 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $11.22 billion in sales this quarter. This is a 8.38 percent decrease over sales of $12.25 billion the same period last year

VLVCY

Volvo Q3 EPS $0.47 Down From $0.64 YoY, Sales $11.22B Down From $12.25B YoY

Sam Altman&#8217;s cryptocurrency-based <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37573206/sam-altmans-worldcoin-halts-id-verification-in-spain-amid-legal-tussle">identity verification project</a> Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>) will now be known as &#8220;World.&#8221; Apart from the rebrand, the team also announced the launch of World Chain, an Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-based Layer-2 network.
What Happened: At an event on Thursday, OpenAI CEO Altman, along with the other executives tied to the project, unveiled several new developments.
The team outlined their plans for &#8220;Orb 2.0,&#8221; an enhanced version of the biometric imaging device that the project uses to collect people's iris in exchange for WLD tokens.
The team also announced the introduction of World Chain, a blockchain that can be customized to meet its specific demands. With 15 million human data points, it was dubbed the &#8220;largest blockchain of humans on day one.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41319774/if-you-invested-1-000-in-bitcoin-when-warren-buffett-called-it-rat-poison-squared-heres-ho?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If You Invested $1,000 In Bitcoin When Warren Buffett Called It &#8216;Rat Poison Squared,&#8217; Here&#8217;s How Much You</a>
Why It Matters: Sam Altman launched the Worldcoin project last year amid significant media attention. 
However, the positive publicity soon transformed into negative publicity as concerns over personal data privacy surfaced. The project has been banned in&nbsp;<a href="https://www.benzinga.com/markets/asia/24/05/38981228/sam-altman-founded-worldcoin-shown-the-door-in-hong-kong-over-privacy-concerns" target="_blank" rel="noreferrer noopener">Hong Kong</a>, Kenya, and&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39176283/sam-altman-founded-worldcoins-suspension-extended-in-spain-crypto-plunges-55-since-march-p" target="_blank" rel="noreferrer noopener">Spain</a>. 
The persistent scrutiny affected the performance of the WLD token, causing it to plunge 40% year-to-date. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Keynote: a new world" width="500" height="281" src="https://www.youtube.com/embed/Ey5bSeUeqqU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: As of this writing, WLD was exchanging hands at $2.21, losing 1.95% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41328586/mark-cuban-dismisses-dogecoin-founders-concerns-kamala-harris-is-night-and-day-away-from-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Arrest Made In SEC X Account Hack Prior To Bitcoin ETF Approval, FBI Says Phone Used To &#8216;Manipulate Financial Markets&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Worldcoin<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$WLD

Sam Altman-Founded Worldcoin Is Changing Its Name To 'World' And Launching Its Own Blockchain — WLD Token's Fortunes Set To Soar?

Reported Earlier, Chinese Unemployment Rate For September 5.1% Vs. 5.3% Est.; 5.3% Prior

Reported Earlier, China Industrial Production Year to Date (YoY) For September 5.8% Vs. 5.8% Prior

Reported Earlier, China Industrial Production (YoY) For September 5.4% Vs. 4.6% Est.; 4.5% Prior

Reported Earlier, China Gross Domestic Product (GDP) Year to Date (YoY) For Q3 4.8% Vs. 5.0% Prior

Reported Earlier, China Gross Domestic Product (YoY) For Q3 4.6% Vs. 4.6% Est.; 4.7% Prior

Reported Earlier, China Gross Domestic Product (QoQ) For Q3 0.9% Vs. 1.0% Est.; 0.7% Prior

Reported Earlier, China Fixed Asset Investment (YoY) For September 3.4% Vs. 3.3% Est.; 3.4% Prior

Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has launched its new desktop trading platform, Robinhood Legend, at the HOOD Summit 2024, signaling a significant shift from its <a href="https://www.benzinga.com/fintech/24/10/41371235/robinhood-announces-futures-trading-index-options-trading">mobile-first approach</a> to a more comprehensive wealth management platform.
What Happened: Chief Brokerage Officer Steve Quirk emphasized the need for this transition, stating, &#8220;About 50% of all retail trading happens on a mobile device and about 50% of it happens on a desktop. We, up to this point, had only been competing on the mobile front. Now we have an alternative.&#8221; Quirk <a href="https://youtu.be/FyaBFs1dZZI?feature=shared">said</a> this in an appearance on CNBCOvertime.
Robinhood Legend is designed to appeal to more sophisticated retail investors, featuring advanced charting capabilities with up to eight simultaneous charts and enhanced technical indicators. 
CEO Vlad Tenev highlighted the initial success of the platform, announcing that the first thousand early access spots were claimed in under a minute, indicating robust demand among users.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41395673/google-reshuffles-search-leadership-while-navigating-ai-threat-to-core-business">Google Reshuffles Search Leadership While Navigating AI Threat To Core Business</a>
Why It Matters: This development follows a series of strategic moves by Robinhood to expand its offerings. The company recently announced the launch of <a href="https://www.benzinga.com/fintech/24/10/41371235/robinhood-announces-futures-trading-index-options-trading">futures trading and index options trading</a> at the HOOD Summit 2024. This was seen as a major expansion of the platform&#8217;s offerings.
Robinhood&#8217;s acquisition of Bitstamp is also expected to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41391989/exclusive-robinhoods-bitstamp-deal-will-drive-growth-exec-says-what-was-good-for-stocks-we">drive growth in its crypto offerings</a>. The company&#8217;s General Manager for Robinhood Crypto, Johann Kerbrat, highlighted the potential impact of this acquisition on the company&#8217;s crypto products.
Robinhood&#8217;s growth has been a topic of <a href="https://www.benzinga.com/markets/options/24/10/41389775/exclusive-cboe-ceo-says-robinhood-growth-an-eye-opener-unpredictable-2024-election-could-increase">discussion in the industry</a>, with CBOE CEO Fred Tomczyk describing it as &#8220;an eye-opener&#8221;. The company&#8217;s expansion into desktop trading is expected to further strengthen its position in the market.
Price Action: Robinhood&#8217;s stock closed at $26.32 on Thursday, down 2.27% for the day. In after-hours trading, the stock saw a slight increase of 0.38%. Year to date, Robinhood&#8217;s stock has experienced growth of 112.77%, according to <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Man Who Accidentally Threw Hard Drive Containing 8,000 Bitcoins Worth Half A Billion Dollars In Landfill Sues Local City Council For Not Excavating The Site</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

HOOD

Robinhood Aims To Capture Beyond 50% Of Mobile Traders With Legend Desktop Platform: 'Now We Have An Alternative'

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan National Consumer Price Index (MoM) For September -0.3% Vs. 0.5% Prior

Reported Earlier, Japan National Core Consumer Price Index (YoY) For September 2.4% Vs. 2.3% Est.; 2.8% Prior

In a recent interview, former President Donald Trump advocated for a significant increase in import tariffs, a move that was slammed by Nobel winning economist Paul Krugman in a recent opinion piece.
What Happened: Trump, known for imposing substantial tariffs during his presidency, is now suggesting tariffs as high as 20 percent, including a 60 percent tariff on imports from China. Economists have voiced their opposition to these proposals, warning that such high tariffs could harm the economy, according to Krugman in his New York Times column. He said he shared a similar view.
The economist also shared the column through X and asked, &#8220;Are Trump's tariff ideas really that bad? No, they're worse.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Are Trump's tariff ideas really that bad? No, they're worse <a href="https://t.co/AgDoAYoVfQ">https://t.co/AgDoAYoVfQ</a>
&mdash; Paul Krugman (@paulkrugman) <a href="https://twitter.com/paulkrugman/status/1847062351997984849?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The former president believes that these high tariffs would reduce U.S. trade deficits and stimulate domestic manufacturing. However, this approach has been widely criticized by economists, who argue that the tariffs would not achieve these goals.
Opining on why Trump favored Tariffs, Krugman wrote, &#8220;It has never been entirely clear why Trump has a thing for tariffs. My guess is that he sees everything in terms of winners, losers and punishment.&#8221;
Trump&#8217;s proposed tariffs, if implemented, could potentially turn the clock back 90 years, raising overall tariffs to levels not seen since the era of the Smoot-Hawley Tariff Act.
Trump&#8217;s proposed tariffs were framed as a plan, they were likely to raise living costs by about 3 to 4 percent, disproportionately affecting middle- and lower-income families. Economists generally agreed that these tariffs would not boost American manufacturing or reduce the trade deficit, and could ultimately harm the economy by increasing global poverty and creating market fragmentation, said Krugman.
&#8220;What the tariffs would do is shrink our economy. They would cause us to sell less of the goods we currently export — that is, stuff we're relatively good at producing — and more stuff we aren't that good at producing. The effect would be to make the economy less efficient and poorer,&#8217; wrote the Economist.
He warned, &#8220;The Trump tariffs could cause a spike in global poverty — and, it's easy to imagine, global conflict.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Financial Sector Hits Record Highs As Goldman Sachs, Bank of America, Citi Beat Q3 Earnings Expectations</a>
Why It Matters: Trump&#8217;s tariff strategy has been a topic of discussion among economists and business leaders. <a href="https://www.benzinga.com/general/politics/24/10/41371990/trump-cant-impose-tariffs-on-china-says-peter-schiff-he-can-only-impose-tariffs-on-americans-who">Peter Schiff</a>, a renowned economist, criticized Trump&#8217;s approach, stating that tariffs would only affect Americans who buy Chinese products.
Similarly, billionaire Mark Cuban <a href="https://www.benzinga.com/news/24/10/41348822/mark-cuban-says-he-knows-what-trump-wants-to-achieve-with-tariffs-but-the-ex-president-has-no-idea-w">expressed his skepticism</a> about Trump&#8217;s approach to revitalizing U.S. manufacturing through tariffs. In a post, Cuban argued that Trump does not understand what it takes to achieve his goals.
Trump defended his tariff strategy during an <a href="https://www.benzinga.com/general/politics/24/10/41344136/trump-goes-on-the-defense-about-massive-effect-of-tariffs-economic-growth-putin-relationship-djt">interview</a> at the Economic Club of Chicago, stating that tariffs have a &#8220;massive effect.&#8221;
Image via Flickr
Read Next: 
Read Next: 
<ul>
<li><a href="EXCLUSIVE: Robinhood's Bitstamp Deal Will Drive Growth, Exec Says: 'What Was Good For Stocks ... We Brought Into Crypto'">EXCLUSIVE: Robinhood&#8217;s Bitstamp Deal Will Drive Growth, Exec Says: &#8216;What Was Good For Stocks … We Brought Into Crypto&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Paul Krugman Warns Trump's Tariff Plan Could Rewind Economic Progress 90 Years and Ignite Global Conflict: 'He Sees Everything In Terms Of Winners, Losers And Punishment'

Entrada Therapeutics GAAP EPS of $1.55, revenue of $94.7M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Entrada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/trda-stock-quote/">TRDA</a>) just reported results for the second quarter of 2024.<ul><li>Entrada Therapeutics reported earnings per share of $1.55. This was above the analyst estimate for EPS of 14 cents.</li><li>The company reported revenue of $94.69 million.</li><li>This was 105.54% better than the analyst estimate for revenue of $46.07 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/trda-stock-earnings-entrada-therapeutics-for-q2-of-2024/">TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report). The company's ...

TD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), retaining the price target o...

Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), with ...

Entrada Therapeutics Inc (TRDA) Gets a Buy from Oppenheimer

Dyne stock tumbles 31% amid drug updates, management changes

Capricor stock rallies 20% on DMD data presentation update

The biotech industry is flourishing with increasing investments and breakthrough developments. Thus, fundamentally solid small-cap biotech stocks BioCryst Pharmaceuticals (BCRX), Harmony Biosciences (HRMY), and Entrada Therapeutics (TRDA) with potential upside could be worth buying. Read more... The biotech industry is experiencing strong growth and expansion amid increasing investments, robust demand, and a boosting IPO market. Also, the recently announced Fed rate cuts will benefit the market operations.
Amid this backdrop, investors could consider investing in solid small-cap biotech stocks BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>), and Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>) for significant upside.
The biotech industry continued to rebound in 2024 with pent-up demand, improving technologies, and an optimistic IPO market. September was marked as the <a href="https://www.reuters.com/markets/deals/camp4-therapeutics-seeks-up-283-mln-valuation-us-ipo-2024-10-07/#:~:text=Oct%207%20(Reuters)%20%2D%20Three,after%20a%20two%2Dyear%20slump.">busiest month for healthcare IPOs</a>, encouraged by some strong debuts.
Also, innovative discoveries in areas like oncology, immunology, and neurology supported by increasing investments are bound to propel the biotech industry's prospects. According to <a href="https://investingnews.com/biotech-forecast/#toggle-gdpr">Biopharma Dive</a>, over 12 deals were reported during the second quarter, totaling 28 this year, reflecting strong biotech mergers and acquisitions (M&amp;A) activities.
Besides, <a href="https://www.biopharmadive.com/news/biotech-interest-rates-impact-startups-venture-capital/727479/">the Fed's decision to cut rates</a> for the first time in more than four years will ease the funding environment and also accelerate early-stage drugmakers' operations, and could potentially spur investments in biotech companies.
In addition, the growing R&amp;D initiatives and adoption of digital technologies worldwide would benefit the industry's growth. As per a report by Precedence Research, the <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion,USD%20521.02%20billion%20in%202023.">global biotechnology market</a> is expected to reach $4.61 trillion by 2034, growing at a CAGR of 11.5%.
Amid this economic and industry background, small-cap biotech stocks offer great potential for high returns and long-term growth for investors. Small-cap stocks are low-cost and have more growth opportunities.
Therefore, let's delve into the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)
BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names, and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
On September 30, BCRX was awarded a $69 million contract by the U.S. Department of Health and Human Services for the procurement of up to 95,625 doses over a five-year period of RAPIVAB&#xAE; (peramivir injection) for treating influenza.
On July 9, BCRX received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru for its oral, once-daily ORLADEYO&#xAE; (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
During the second quarter that ended June 30, 2024, BCRX's total revenues grew 32.5% from the prior year's quarter to $109.33 million. The company's adjusted income from operations was $21.93 million for the quarter.
Furthermore, the company's cash, cash equivalents and, investments and total assets were $336.34 million and $472.42 million as of June 30, 2024.
Analysts expect BCRX's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the third quarter (ended September 2024) to grow 31.3% year-over-year to $113.89 million. Its revenue for the fiscal year 2024 is expected to grow 30.9% year-over-year to $433.84 million. Also, the company topped the consensus revenue estimates in all of the four trailing quarters.
Shares of BCRX have surged 56.2% over the past six months and 17.1% over the past year to close the last trading session at $7.20. Moreover, Wall Street analysts expect the stock to reach $15.33 in the upcoming 12 months, indicating a <a href="https://www.tipranks.com/stocks/bcrx/forecast">potential upside of 116.07%</a>.
BCRX's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
BCRX has a B grade for Quality, Growth, and Value. It is ranked #21 out of 331 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have BCRX ratings for Sentiment, Momentum, and Stability. Get all BCRX ratings <a href="https://stocknews.com/stock/BCRX/">here</a>.
Stock #2: Harmony Biosciences Holdings, Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>)
HRMY is a commercial-stage pharmaceutical company that focuses on developing and commercializing therapies for patients with rare and other neurological diseases. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action to treat excessive daytime sleepiness in adult patients with narcolepsy.
On June 24, HRMY announced that the U.S. FDA approved its supplemental New Drug Application (sNDA) for WAKIX&#xAE; (pitolisant) tablets treating excessive daytime sleepiness (EDS) in pediatric patients six years of age and older with narcolepsy. With this, WAKIX became the first FDA-approved non-scheduled treatment for pediatric narcolepsy patients.
During the second quarter that ended June 30, 2024, HRMY's net product revenue increased 28.8% year-over-year to $172.81 million. Its gross profit increased 28.8% from the year-ago value to $140.67 million. The company's non-GAAP adjusted net income and EPS came in at $60.61 million and $1.05 per share, up 32.1% and 38.1% from the prior year's quarter, respectively.
Additionally, the company's total assets stood at $858.38 million as of June 30, 2024, compared to $811.45 million as of December 31, 2023.
Street expects HRMY's revenue for the third quarter (ended September 2024) to increase 15.3% year-over-year to $184.81 million, while its EPS is expected to grow 7.2% year-over-year to $0.68, respectively. Furthermore, the company surpassed the consensus revenue estimates in all of the trailing four quarters.
HRMY's stock has gained 16.5% over the past six months and 6.6% over the past year to close the last trading session at $34.75. Wall Street expects the stock to reach $52 in the near term, indicating a <a href="https://www.tipranks.com/stocks/hrmy/forecast">potential upside of 49.38%</a>.
HRMY's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has an A grade for Value and a B grade for Quality. HRMY is ranked #14 among 331 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/HRMY/">Click here</a> to access HRMY's ratings for Momentum, Growth, Stability, and Sentiment.
Stock #1: Entrada Therapeutics, Inc. (<a href="https://stocknews.com/stock/TRDA/">TRDA</a>)
TRDA is a clinical-stage biotechnology company that develops endosomal escape vehicle therapeutics for treating multiple neuromuscular diseases. The company's EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
On June 24, TRDA announced positive preliminary data from its Phase 1 clinical trial, ENTR-601-44-101. It reported that ENTR-601-44 was taken well by healthy volunteers with no serious or drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams, or laboratory assessments.
ENTR-601-44 also showed significant plasma concentration, muscle concentration, and exon skipping at levels suggesting potential for a clinically meaningful starting dose in planned upcoming patient trials.
During the second quarter, which ended June 30, 2024, TRDA's collaboration revenue increased 421.1% year-over-year to $94.69 million, and its income from operations was $53.42 million for the same period. The company's net income amounted to $55.03 million or $1.55 per share, against a net loss of $25.93 million and $0.78 per share during the prior year's quarter, respectively.
Street expects TRDA's revenue for the fiscal year (ending December 2024) to increase 36.3% year-over-year to $175.89 million, and its EPS for the same period is expected to be $0.62. Also, the company has surpassed the consensus revenue estimates in each of the trailing four quarters, which is impressive.
TRDA's stock has gained 21.9% over the past six months and 15% over the past year to close the last trading session at $16.39. Also, Wall Street analysts expect the stock to reach $21.50 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/trda/forecast">upside of 32.55%</a>.
TRDA's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and Quality. It also has a B grade for Sentiment. Within the same industry, TRDA is ranked #13 among 331 stocks.
<a href="https://stocknews.com/stock/TRDA/">Click here</a> to access additional ratings of TRDA for Momentum, Growth, and Stability.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HRMY shares were unchanged in after-hours trading Wednesday. Year-to-date, HRMY has gained 4.02%, versus a 22.57% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/hrmy-bcrx-trda-3-small-cap-biotech-stocks-to-buy-for-major-upside/>3 Small-Cap Biotech Stocks to Buy for Major Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Biotech Stocks to Buy for Major Upside

Capitulation in biotech is near, as well as a rally – Piper Sandler

Capricor reports positive long-term data for DMD drug deramiocel

ASMB

BCRX

CAPR

CDNA

CPRX

DTIL

EWTX

EXEL

HRMY

IBBQ

IDNA

MSCLF

NTRA

PEPG

PRAX

PTGX

RGNX

RHHBY

SLDB

SPRY

SRPT

TRDA

VRTX

Press Releases

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Health Care

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Management

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Comments

Entrada Therapeutics

Notizie

Ultime notizie per Entrada Therapeutics (NASDAQ:TRDA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO